Allegion plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Allegion plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.41B | Feb 20, 2018 |
| FY2017 | Dec 31, 2016 | $2.24B | Feb 20, 2018 |
| FY2017 | Dec 31, 2015 | $2.07B | Feb 20, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.07B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.77B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $3.65B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $3.27B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $2.87B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $2.72B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $2.85B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $2.73B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $2.41B | Feb 18, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $2.73B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $2.41B | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $2.24B | Feb 19, 2019 |
| FY2017 | Dec 31, 2015 | $2.07B | Feb 20, 2018 |
| FY2016 | Dec 31, 2014 | $2.12B | Feb 17, 2017 |
| FY2015 | Dec 31, 2013 | $2.07B | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $2.02B | Feb 27, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $643.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $597.50M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $540.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $458.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $483.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $314.30M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $401.80M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $434.90M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $273.30M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $229.10M | Feb 19, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $859.50M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $780.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $708.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $586.40M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $530.20M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $403.50M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $565.10M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $525.80M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $492.50M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $434.30M | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $112.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $101.90M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $74.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $73.30M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $54.40M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $54.70M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $54.40M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $48.30M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $47.30M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $978.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $887.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $865.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $736.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $674.70M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $635.70M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $681.30M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $647.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $580.40M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $555.40M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $783.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $675.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $600.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $459.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $488.60M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $490.30M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $488.20M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $457.80M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $347.20M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $377.50M | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $92.10M | Feb 18, 2025 |
| FY2024 | Dec 31, 2023 | $84.20M | Feb 18, 2025 |
| FY2024 | Dec 31, 2022 | $64.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $45.40M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $47.10M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $65.60M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $49.10M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $49.30M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $42.50M | Feb 19, 2019 |
| FY2017 | Dec 31, 2015 | $35.20M | Feb 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.22B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.49B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $4.31B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $3.99B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $3.05B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $3.07B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $2.97B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $2.81B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $2.54B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $2.25B | Feb 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.16B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.99B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.99B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.05B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $2.29B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $2.24B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.21B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $2.16B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $2.14B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $2.13B | Feb 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.32B | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | $941.80M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $759.10M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $829.40M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $757.40M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $651.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $401.60M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $113.30M | Feb 20, 2018 |
| FY2016 | Dec 31, 2015 | $25.60M | Feb 17, 2017 |
| FY2015 | Dec 31, 2014 | ($4.80M) | Feb 26, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.91B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.49B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.44B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.41B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $803.80M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $819.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $873.30M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $883.00M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $761.20M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $716.80M | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.24B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.83B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.58B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.21B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $952.60M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $985.60M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $975.10M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $873.60M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $544.40M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $376.60M | Feb 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $356.20M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $503.80M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $468.10M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $288.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $397.90M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $480.40M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $355.30M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $283.80M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $466.20M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $312.40M | Feb 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.98B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.00B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.02B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.09B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.44B | Feb 22, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 6 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 4 | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 19, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 6 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 4 | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 19, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 86.07M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 86.25M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 87.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 87.85M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 88.22M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 91.21M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | 92.72M | Feb 16, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $175.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $167.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $158.70M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $143.90M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $129.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $117.30M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $100.60M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $79.40M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $60.90M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $46.00M | Feb 19, 2019 |